CRVS
Price
$7.04
Change
-$0.61 (-7.97%)
Updated
Oct 17 closing price
Capitalization
524.58M
12 days until earnings call
Intraday Buy/Sell Signals
GLMD
Price
$1.37
Change
-$0.04 (-2.84%)
Updated
Oct 17 closing price
Capitalization
7.51M
23 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

CRVS vs GLMD

Header iconCRVS vs GLMD Comparison
Open Charts CRVS vs GLMDBanner chart's image
Corvus Pharmaceuticals
Price$7.04
Change-$0.61 (-7.97%)
Volume$989.99K
Capitalization524.58M
Galmed Pharmaceuticals
Price$1.37
Change-$0.04 (-2.84%)
Volume$116.91K
Capitalization7.51M
CRVS vs GLMD Comparison Chart in %
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. GLMD commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and GLMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (CRVS: $7.04 vs. GLMD: $1.37)
Brand notoriety: CRVS and GLMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 129% vs. GLMD: 84%
Market capitalization -- CRVS: $524.58M vs. GLMD: $7.51M
CRVS [@Biotechnology] is valued at $524.58M. GLMD’s [@Biotechnology] market capitalization is $7.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileGLMD’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • GLMD’s FA Score: 1 green, 4 red.
According to our system of comparison, GLMD is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 3 TA indicator(s) are bullish while GLMD’s TA Score has 4 bullish TA indicator(s).

  • CRVS’s TA Score: 3 bullish, 5 bearish.
  • GLMD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GLMD is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а +1.59% price change this week, while GLMD (@Biotechnology) price change was -3.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

CRVS is expected to report earnings on Oct 30, 2025.

GLMD is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($525M) has a higher market cap than GLMD($7.51M). CRVS YTD gains are higher at: 31.589 vs. GLMD (-57.053). GLMD has higher annual earnings (EBITDA): -7.03M vs. CRVS (-35.45M). CRVS has more cash in the bank: 74.4M vs. GLMD (20.5M). GLMD has less debt than CRVS: GLMD (41K) vs CRVS (1.08M). CRVS (0) and GLMD (0) have equivalent revenues.
CRVSGLMDCRVS / GLMD
Capitalization525M7.51M6,993%
EBITDA-35.45M-7.03M504%
Gain YTD31.589-57.053-55%
P/E RatioN/A0.02-
Revenue00-
Total Cash74.4M20.5M363%
Total Debt1.08M41K2,641%
FUNDAMENTALS RATINGS
CRVS vs GLMD: Fundamental Ratings
CRVS
GLMD
OUTLOOK RATING
1..100
7363
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
9996
SEASONALITY SCORE
1..100
5031

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLMD's Valuation (30) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRVS (67) in the Pharmaceuticals Major industry. This means that GLMD’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (73) in the Pharmaceuticals Major industry is in the same range as GLMD (100) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew similarly to GLMD’s over the last 12 months.

CRVS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as GLMD (98) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew similarly to GLMD’s over the last 12 months.

CRVS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as GLMD (65) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew similarly to GLMD’s over the last 12 months.

GLMD's P/E Growth Rating (96) in the Pharmaceuticals Other industry is in the same range as CRVS (99) in the Pharmaceuticals Major industry. This means that GLMD’s stock grew similarly to CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSGLMD
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBMVX54.65N/A
N/A
Neuberger Berman Small Cap Growth Adv
PRGTX26.47N/A
N/A
T. Rowe Price Global Technology
NGISX18.48N/A
N/A
Nationwide BNY Mellon Dyn US Core I.S
KCSSX13.76N/A
N/A
Knights of Columbus Small Cap S
RBCIX12.70N/A
N/A
RBC China Equity I

GLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLMD has been closely correlated with XBIO. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLMD jumps, then XBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLMD
1D Price
Change %
GLMD100%
-2.84%
XBIO - GLMD
88%
Closely correlated
-4.10%
GBIO - GLMD
32%
Poorly correlated
-6.93%
JSPR - GLMD
31%
Poorly correlated
-1.21%
CDTX - GLMD
28%
Poorly correlated
-0.49%
CRVS - GLMD
28%
Poorly correlated
-7.97%
More